Possible Determinants of VSL#3 Probiotic Failure in Preventing Gastrointestinal Adverse Events Associated With Dacomitinib in Patients With Advanced Non-Small-Cell Lung Cancer Enrolled in ARCHER-1042 Trial

Annals of Oncology - United Kingdom
doi 10.1093/annonc/mdw298
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Chemoradiotherapy Followed by Durvalumab in Patients With Unresectable Advanced Non‐small Cell Lung Cancer: Management of Adverse Events

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Proactive Management Strategies for Potential Gastrointestinal Adverse Reactions With Ceritinib in Patients With Advanced ALK-positive Non-Small-Cell Lung Cancer

Cancer Management and Research
Oncology
2016English

Association Between Adverse Events and Quality of Life in Patients Treated With Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Circadian Function in Patients With Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

Discovering Associations of Adverse Events With Pharmacotherapy in Patients With Non-Small Cell Lung Cancer Using Modified Apriori Algorithm

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2018English

Nondisruptive P53 Mutations Are Associated With Shorter Survival in Patients With Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

A Phase I Trial of Temsirolimus and Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer

Chemotherapy
MedicineDrug DiscoveryInfectious DiseasesOncologyPharmacology
2016English

P3.01-100 Risk of Gastrointestinal and Hepatic Toxicities in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Osimertinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy